Paddy Kalish OD

09/01/2025

For people with macular telangiectasia type 2 (MacTel), an orphan retinal disorder that gradually destroys central vision, there have long been no approved treatment options. But now, a new study sponsored by Neurotech Pharmaceuticals and spearheaded by investigators at Scripps Research and the Nati...

08/27/2025

08/27/2025

08/18/2025

https://www.facebook.com/share/v/15Qs7vi3Pj/?mibextid=wwXIfr

08/06/2025

: A single administration of MCO-010 (Nanoscope Therapeutics) optogenetic therapy improves visual acuity in patients with severe vision loss due to retinitis pigmentosa (RP), according to research presented at the American Society of Retina Specialists annual meeting, held July 30 to August 2 in Long Beach, California. The research also shows that the therapy is well-tolerated.

Lead study author David Liao, MD, PhD, and colleagues sought to assess the long-term efficacy and safety of MCO-010, a mutation-agnostic optogenetic therapy, in patients with severe vision loss caused by retinitis pigmentosa.

Read more: https://bit.ly/4myTTQV

07/21/2025

Identifying the correct uveitis type can help reveal underlying systemic infections, neoplastic conditions, and other systemic illnesses.

07/14/2025

This case report describes a diagnosis of inverted hyperoleon in a patient who underwent retinal detachment repair using high-molecular-weight silicone oil.

07/10/2025

07/05/2025

What’s the Name of this Syndrome?

03/22/2025

Patients with amaurosis fugax have a higher risk of stroke, retinal artery occlusion, transient ischemic attack, and carotid stenosis within 12 months compared to matched controls. https://ja.ma/4iOuFMK

03/21/2025

Science Fiction: Marslings, Children of MARS

03/13/2025

Individuals with atopic dermatitis (AD), both active and prior cases, have a higher prevalence of ocular surface disease (OSD) symptoms, worse self-rated vision, and poorer overall health compared with those who have never had AD, according to study results published in Dermatitis.

Read here: https://bit.ly/4kIx90B